

2. It is expected that the net Company for the First Half of 2019 will be approximately RMB-136,263,300, and will be higher than the corresponding period of last year.

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



3. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the First Half of 2024 will be approximately RMB-220,600,500 to RMB-163,052,500. In particular:

3.1 Net profit from laboratory services business will be approximately RMB-28,291,700 to RMB10,941,100.

3.2 Net loss from changes in fair value of biological assets will be approximately RMB223,589,900 to RMB247,125,600.

3.3 Net profit from gains on fund management will be approximately RMB49,596,200 to RMB54,816,900.

*Note:*

Net profit from laboratory services business: the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses after excluding the effects of gains or losses from changes in fair value of biological assets and interest income and exchange gains or losses.

(III) The estimated results have not been audited by certified public accountants.

## **II. RESULTS FOR THE CORRESPONDING PERIOD OF THE PREVIOUS YEAR**

1. Revenue of the Company: RMB1,012,077,300.

2. Net profit attributable to the shareholders of the Company: RMB90,627,200.

3. Net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses: RMB76,886,500. In particular:

3.1 Net profit from laboratory services business: RMB195,323,100.

3.2 Net profit from changes in fair value of biological assets: RMB182,987,600.

3.3 Net profit from gains on fund management: RMB64,550,900.

4. Earnings per share: RMB0.17.

### **III. MAIN REASONS FOR THE CHANGES IN RESULTS DURING THE CURRENT PERIOD**

- (I) During the reporting period, there was a decrease in the Company's revenue due to the impact of the investment and financing enthusiasm in the pharmaceutical industry and changes in market demand. Intensified competition in the industry led to a compression of profit margins on sales orders, resulting in a year-on-year decrease in gross profit margin of the Company. The net profit of the Company's laboratory services business significantly declined year-on-year, potentially resulting in a minor loss.
- (II) During the reporting period, the Company experienced ongoing negative effects on results due to loss on fair value changes of biological assets held by the Company driven by a decline in market prices.

### **IV. RISK WARNING**

There are no material uncertainties affecting the accuracy of the estimated results.

### **V. OTHER EXPLANATION**

As the Company is still in the process of preparing and finalizing its interim results announcement of 2024, the information contained in this announcement is only based on the preliminary assessment by the Company on the unaudited consolidated management